Recombinant Human DNase I Purification via Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying recombinant human DNase I (rhDNase I) are inefficient and may contain contaminants, leading to adverse events in patients with cystic fibrosis, necessitating the development of a more effective purification process.
Innovation Solution
A method involving a combination of anion-exchange column chromatography, column chromatography with a material having affinity for phosphate groups, cation-exchange column chromatography, and dye ligand affinity column chromatography is used to purify rhDNase I from culture supernatant of mammalian cells grown in serum-free medium, achieving high purity and specific activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current purification methods are used for rhDNase I, then the production process is simpler, but the purity is insufficient and contaminants remain leading to adverse events
Solution Approach 1:
The purification process is divided into multiple sequential chromatography steps, each targeting specific contaminants. The method segments the purification task into: (1) anion-exchange chromatography to remove deamidated rhDNase I, (2) heparin column chromatography to remove additional impurities, and (3) cation-exchange chromatography for final purification. This segmentation allows each step to address specific contamination issues, achieving high purity while maintaining manageable process complexity.
Solution Approach 2:
The invention introduces calcium ions as an intermediary substance to inhibit aggregation of rhDNase I during the purification process. By adding calcium ions at specific concentrations (1-10 mM) during chromatography steps, the method prevents protein aggregation that would otherwise occur, ensuring high purity without requiring additional complex processing steps to handle aggregated material.
2Manufacturing precision
If multiple chromatography steps are added to improve purity, then the purity of rhDNase I increases, but the production time and process complexity increase
Solution Approach 1:
The method performs preliminary removal of the most abundant contaminant (deamidated rhDNase I) through anion-exchange chromatography as the first step. By eliminating this major impurity early in the process, subsequent chromatography steps can focus on removing lesser contaminants more efficiently, reducing the total time required compared to attempting to remove all contaminants simultaneously in later steps.
Solution Approach 2:
The invention optimizes various parameters across the chromatography steps to reduce processing time while maintaining purity. This includes adjusting buffer compositions, flow rates, and pH values for each chromatography step to achieve optimal separation efficiency. The use of calcium ions at optimized concentrations also accelerates the process by preventing aggregation that would require additional processing time to resolve.
3Reliability
If deamidated rhDNase I is not removed, then the production process is faster and simpler, but adverse events occur in patients due to contamination
Solution Approach 1:
The invention specifically targets and extracts deamidated rhDNase I from the mixture using anion-exchange chromatography as the first purification step. This contaminant, which causes adverse events in patients, is separated from the native rhDNase I based on their different charge properties. The extracted deamidated form is then discarded, ensuring patient safety while maintaining high productivity through efficient single-step removal of this specific contaminant.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method efficiently produces rhDNase I with high purity and specific activity, suitable for use as a medicament for cystic fibrosis, reducing the risk of adverse events and improving treatment efficacy.
Implementation Method 1
anion-exchange column chromatography
Implementation Method 2
column chromatography with a material having affinity for phosphate groups
Implementation Method 3
cation-exchange column chromatography
Implementation Method 4
dye ligand affinity column chromatography
Data Source
AI summary
Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.